PortfoliosLab logoPortfoliosLab logo
SMID vs. CORT
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

SMID vs. CORT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Smith-Midland Corporation (SMID) and Corcept Therapeutics Incorporated (CORT). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, SMID achieves a -15.16% return, which is significantly lower than CORT's 115.20% return. Both investments have delivered pretty close results over the past 10 years, with SMID having a 28.70% annualized return and CORT not far ahead at 29.31%.


SMID

1D
2.94%
1M
-11.02%
YTD
-15.16%
6M
-9.51%
1Y
5.11%
3Y*
20.27%
5Y*
12.19%
10Y*
28.70%

CORT

1D
3.08%
1M
45.90%
YTD
115.20%
6M
-11.54%
1Y
7.02%
3Y*
47.73%
5Y*
28.46%
10Y*
29.31%
*Multi-year figures are annualized to reflect compound growth (CAGR)

SMID vs. CORT - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
SMID
Smith-Midland Corporation
-15.16%-18.26%12.56%92.68%-56.38%397.35%57.50%-18.98%9.99%29.02%
CORT
Corcept Therapeutics Incorporated
115.20%-30.94%55.14%59.92%2.58%-24.31%116.20%-9.43%-26.02%148.76%

Correlation

The correlation between SMID and CORT is 0.10, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.10

Correlation (3Y)
Calculated over the trailing 3-year period

0.13

Correlation (5Y)
Calculated over the trailing 5-year period

0.15

Correlation (10Y)
Calculated over the trailing 10-year period

0.10

Correlation (All Time)
Calculated using the full available price history since Jan 5, 2016

0.10

Fundamentals

EPS

SMID:

$3.54

CORT:

$0.41

PE Ratio

SMID:

8.72

CORT:

182.61

PEG Ratio

SMID:

0.04

CORT:

90.97

PS Ratio

SMID:

1.17

CORT:

11.30

Total Revenue (TTM)

SMID:

$93.45M

CORT:

$769.10M

Gross Profit (TTM)

SMID:

$26.04M

CORT:

$755.64M

EBITDA (TTM)

SMID:

$19.01M

CORT:

$3.66M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

SMID vs. CORT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SMID
SMID Risk / Return Rank: 4444
Overall Rank
SMID Sharpe Ratio Rank: 4545
Sharpe Ratio Rank
SMID Sortino Ratio Rank: 4343
Sortino Ratio Rank
SMID Omega Ratio Rank: 4242
Omega Ratio Rank
SMID Calmar Ratio Rank: 4545
Calmar Ratio Rank
SMID Martin Ratio Rank: 4545
Martin Ratio Rank

CORT
CORT Risk / Return Rank: 4747
Overall Rank
CORT Sharpe Ratio Rank: 4444
Sharpe Ratio Rank
CORT Sortino Ratio Rank: 4747
Sortino Ratio Rank
CORT Omega Ratio Rank: 5757
Omega Ratio Rank
CORT Calmar Ratio Rank: 4444
Calmar Ratio Rank
CORT Martin Ratio Rank: 4343
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SMID vs. CORT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Smith-Midland Corporation (SMID) and Corcept Therapeutics Incorporated (CORT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SMIDCORTDifference
Sharpe ratioReturn per unit of total volatility

+0.01

Sortino ratioReturn per unit of downside risk

-0.17

Omega ratioGain probability vs. loss probability

1.06

1.14

-0.08

Calmar ratioReturn relative to maximum drawdown

0.13

0.11

+0.02

Martin ratioReturn relative to average drawdown

0.28

0.20

+0.08

SMID vs. CORT - Sharpe Ratio Comparison

The current SMID Sharpe Ratio is 0.10, which is comparable to the CORT Sharpe Ratio of 0.09. The chart below compares the historical Sharpe Ratios of SMID and CORT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


SMIDCORTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.10

0.09

+0.01

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.19

0.38

-0.19

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.54

0.44

+0.10

Sharpe Ratio (All Time)

Calculated using the full available price history

0.47

0.11

+0.35

Drawdowns

SMID vs. CORT - Drawdown Comparison

The maximum SMID drawdown since its inception was -72.37%, smaller than the maximum CORT drawdown of -94.28%. Use the drawdown chart below to compare losses from any high point for SMID and CORT.


Loading charts...

Drawdown Indicators


SMIDCORTDifference

Max Drawdown

Largest peak-to-trough decline

-72.37%

-94.28%

+21.91%

Max Drawdown (1Y)

Largest decline over 1 year

-39.29%

-64.40%

+25.11%

Max Drawdown (3Y)

Largest decline over 3 years

-48.85%

-71.85%

+23.00%

Max Drawdown (5Y)

Largest decline over 5 years

-72.37%

-71.85%

-0.52%

Max Drawdown (10Y)

Largest decline over 10 years

-72.37%

-71.85%

-0.52%

Current Drawdown

Current decline from peak

-38.38%

-34.43%

-3.95%

Average Drawdown

Average peak-to-trough decline

-27.51%

-53.45%

+25.94%

Ulcer Index

Depth and duration of drawdowns from previous peaks

18.26%

35.30%

-17.04%

Volatility

SMID vs. CORT - Volatility Comparison

Smith-Midland Corporation (SMID) has a higher volatility of 16.95% compared to Corcept Therapeutics Incorporated (CORT) at 16.12%. This indicates that SMID's price experiences larger fluctuations and is considered to be riskier than CORT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


SMIDCORTDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.95%

16.12%

+0.83%

Volatility (6M)

Calculated over the trailing 6-month period

39.15%

85.09%

-45.94%

Volatility (1Y)

Calculated over the trailing 1-year period

52.88%

76.52%

-23.64%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

64.79%

74.51%

-9.72%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

54.16%

67.19%

-13.03%

Dividends

SMID vs. CORT - Dividend Comparison

Neither SMID nor CORT has paid dividends to shareholders.


PositionTTM2025202420232022202120202019201820172016
CORT
Corcept Therapeutics Incorporated
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
SMID
Smith-Midland Corporation
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.92%0.74%0.73%0.19%

Financials

SMID vs. CORT - Financials Comparison

This section allows you to compare key financial metrics between Smith-Midland Corporation and Corcept Therapeutics Incorporated. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M20222023202420252026
23.11M
164.90M
(SMID) Total Revenue
(CORT) Total Revenue
Values in USD except per share items

SMID vs. CORT - Profitability Comparison

The chart below illustrates the profitability comparison between Smith-Midland Corporation and Corcept Therapeutics Incorporated over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20222023202420252026
23.9%
98.3%
Portfolio components
SMID - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Smith-Midland Corporation reported a gross profit of 5.52M and revenue of 23.11M. Therefore, the gross margin over that period was 23.9%.

CORT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a gross profit of 162.02M and revenue of 164.90M. Therefore, the gross margin over that period was 98.3%.

SMID - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Smith-Midland Corporation reported an operating income of 3.24M and revenue of 23.11M, resulting in an operating margin of 14.0%.

CORT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported an operating income of -49.60M and revenue of 164.90M, resulting in an operating margin of -30.1%.

SMID - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Smith-Midland Corporation reported a net income of 2.13M and revenue of 23.11M, resulting in a net margin of 9.2%.

CORT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Corcept Therapeutics Incorporated reported a net income of -31.20M and revenue of 164.90M, resulting in a net margin of -18.9%.


Frequently Asked Questions


SMID and CORT have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

SMID has higher volatility (16.95%) compared to CORT (16.12%). In terms of maximum drawdown, SMID dropped -72.37% vs CORT's -94.28%.

SMID currently has the higher Sharpe Ratio (0.10 vs 0.09), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for SMID and CORT

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer